Pharmacological therapy for therapy-resistant depression: New developments;Pharmakotherapie bei therapieresistenter depression: Neue entwicklungen

Nervenarzt

Volumn 78, Issue SUPPL. 3, 2007, Pages 551-564

  Tadic A ^a   Lieb, K ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Antidepressant combination; Antidepressants; Augmentation; Pharmacotherapy; Treatment resistant depression (TRD)

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DESVENLAFAXINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM SALT; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NORCLOMIPRAMINE; NORFLUOXETINE; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

BRAIN DEPTH STIMULATION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ELECTROCONVULSIVE THERAPY; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; PSYCHOTHERAPY; REMISSION; REVIEW; SYMPTOM;

ANTIDEPRESSIVE AGENTS; BRAIN; BUSPIRONE; DEPRESSIVE DISORDER; DRUG INTERACTIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; TRIIODOTHYRONINE;

EID: 35848944693     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-007-2366-1     Document Type: Review

References (15)

1. AkdÄ (Arzneimittelkommission der deutschen Ärzteschaft) (2006) Empfehlungen zur Therapie der Depression, 2. Aufl. Arzneiverordnung in der Praxis 33: Sonderheft 1
2. Anderson IM (2000) Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58: 19-36
3. Bauer M, Bschor T, Pfennig A et al., WFSBP Task Force on Unipolar Depressvie Disorders (2007) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 8: 67-104
4. Baumann P, Hiemke C, Ulrich S et al.; Arbeitsgemeinschaft fur Neuropsychopharmakologie und -pharmakopsychiatrie (2004) The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37: 243-265
5. Benkert O, Hippius H (2006) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin Heidelberg New York
6. Dodd S, Horgan D, Malhi GS et al. (2005) To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord 89: 1-11
7. Herpfer I, Lieb K (2005) Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 19: 275-293
8. Leitner I, Bailer U, Letmaier M et al. (2004) Behandlungsmö glichkeiten der therapieresistenten Depression. J Neurol Neurochir Psychiatr 1: 28-38
9. Lieb K (2005) Affektive Störungen. In: Brunnhuber S, Frauenknecht S, Lieb K (Hrsg) Intensivkurs Psychiatrie. Urban & Fischer Elsevier, München Jena
10. Nierenberg AA, Katz J, Fava M (2007) A critical overview of the pharmacologic management of treatment-resistent depression. Psychiatr Clin N Am 30: 13-29
11. Ruhe HG, Huyser J, Swinkels JA et al. (2006) Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 67: 1836-1855
12. Shams ME, Arneth B, Hiemke C et al. (2006) CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 31: 493-502
13. Szegedi A, Müller MJ, Anghelescu IG et al. (2003) Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 64: 413-420
14. Tadic A, Müller MJ, Rujescu D et al. (2007) The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet 144: 325-331
15. Trivedi MH, Rush AJ, Wisniewski SR et al.; STAR*D Study Team. (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163: 28-40